Elliott J Mufson1, Sue Leurgans. 1. Department of Neurological Sciences, Rush University Medical Center, Chicago, IL, USA. emufson@rush.edu
Abstract
BACKGROUND: Oxidative stress has been implicated in the pathogenesis of Alzheimer's disease (AD). The pathobiological changes related to AD occur long before the overt clinical symptoms. The plasma lipid peroxidation enzyme F2-isoprostane has been suggested as a biomarker to detect the progression from mild cognitive impairment (MCI) to AD. OBJECTIVE: To test whether plasma and urine F2-isoprostane was diagnostic for dementia in living people. METHODS: Plasma and urine were collected from 222 Religious Orders Study participants with a clinical diagnosis of no cognitive impairment, MCI or AD at time of fluid collection. Isoprostane levels were determined using gas chromatography/mass spectroscopy. RESULTS: Plasma and urine F2-isoprostane levels did not differ between the three clinical groups. Postmortem neuropathologic diagnosis of subjects who died during the course of the study was not associated with baseline blood or plasma F2-isoprostane levels. CONCLUSIONS: In living people, plasma or urine isoprostane levels were not sensitive enough to discriminate between individuals with a clinical diagnosis of no cognitive impairment, MCI or AD. Copyright 2010 S. Karger AG, Basel.
BACKGROUND: Oxidative stress has been implicated in the pathogenesis of Alzheimer's disease (AD). The pathobiological changes related to AD occur long before the overt clinical symptoms. The plasma lipid peroxidation enzyme F2-isoprostane has been suggested as a biomarker to detect the progression from mild cognitive impairment (MCI) to AD. OBJECTIVE: To test whether plasma and urine F2-isoprostane was diagnostic for dementia in living people. METHODS: Plasma and urine were collected from 222 Religious Orders Study participants with a clinical diagnosis of no cognitive impairment, MCI or AD at time of fluid collection. Isoprostane levels were determined using gas chromatography/mass spectroscopy. RESULTS: Plasma and urine F2-isoprostane levels did not differ between the three clinical groups. Postmortem neuropathologic diagnosis of subjects who died during the course of the study was not associated with baseline blood or plasma F2-isoprostane levels. CONCLUSIONS: In living people, plasma or urine isoprostane levels were not sensitive enough to discriminate between individuals with a clinical diagnosis of no cognitive impairment, MCI or AD. Copyright 2010 S. Karger AG, Basel.
Authors: Thomas J Montine; Kathleen S Montine; Wendy McMahan; William R Markesbery; Joseph F Quinn; Jason D Morrow Journal: Antioxid Redox Signal Date: 2005 Jan-Feb Impact factor: 8.401
Authors: M S Forman; E J Mufson; S Leurgans; D Pratico; S Joyce; S Leight; V M-Y Lee; J Q Trojanowski Journal: Neurology Date: 2007-03-06 Impact factor: 9.910
Authors: J M Ringman; S G Younkin; D Pratico; W Seltzer; G M Cole; D H Geschwind; Y Rodriguez-Agudelo; B Schaffer; J Fein; S Sokolow; E R Rosario; K H Gylys; A Varpetian; L D Medina; J L Cummings Journal: Neurology Date: 2008-05-28 Impact factor: 9.910
Authors: Luis F Gonzalez-Cuyar; Joshua A Sonnen; Kathleen S Montine; C Dirk Keene; Thomas J Montine Journal: Curr Neurol Neurosci Rep Date: 2011-10 Impact factor: 5.081
Authors: Thomas J Montine; Elaine R Peskind; Joseph F Quinn; Angela M Wilson; Kathleen S Montine; Douglas Galasko Journal: Neuromolecular Med Date: 2010-07-15 Impact factor: 3.843
Authors: Tharusha Jayasena; Anne Poljak; Nady Braidy; George Smythe; Mark Raftery; Mark Hill; Henry Brodaty; Julian Trollor; Nicole Kochan; Perminder Sachdev Journal: PLoS One Date: 2015-03-18 Impact factor: 3.240